Neuroepigenetics

Our aim is to describe the DNA methylation pattern and its influence on the development of neurological diseases, as well as identify epigenetic biomarkers for diagnosis, prognosis and therapeutic monitoring. To this end, we use advanced techniques and procedures of Personalized and Precision Medicine, such as liquid biopsy, ELISA and digital PCR. Our main area of interest is neurodegenerative diseases and post-stroke cognitive decline. In addition, we work to define the epigenetic bases involved in adult neurogenesis and that influence both neurodegeneration and resilience to these processes, in order to find therapeutic targets. Our research incorporates the analysis of sex- and gender- related differences across the different pathologies.

Research lines:
•    Identification of Epigenetic Biomarkers in Alzheimer's disease and other Neurodegenerative Diseases.
•    Precision and Personalized Medicine in the diagnosis of dementias.
•    Mechanisms of neurogenesis and resilience in Alzheimer's disease: new therapeutic targets.
•    Identification of Epigenetic Biomarkers of post-stroke cognitive impairment (PSCI).

The group belongs to the ISCIII RICORS network for cerebrovascular diseases, to the national DEGESCO consortium (Dementia Genetics Spanish Consortium) and participates in the SCAP-AD (IMPACT 2022, ISCIII) Personalized and Precision Medicine project.